<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "17: incur losses", fill: "#a99a86"},
{source: "17: incur losses", target: "17: next several years as", fill: "#a99a86"},
{source: "17: next several years as", target: "17: collaborators", fill: "#a99a86"},
{source: "17: collaborators", target: "17: licensees pursue", fill: "#a99a86"},
{source: "17: licensees pursue", target: "17: clinical trials", fill: "#a99a86"},
{source: "17: clinical trials", target: "17: development efforts", fill: "#a99a86"},
{source: "17: incur losses", target: "18: become profitable", fill: "#c5b358"},
{source: "18: become profitable", target: "18: either alone", fill: "#c5b358"},
{source: "18: either alone", target: "18: collaborators", fill: "#c5b358"},
{source: "18: collaborators", target: "18: licensees must successfully", fill: "#c5b358"},
{source: "18: licensees must successfully", target: "18: manufacture", fill: "#c5b358"},
{source: "18: manufacture", target: "18: current product candidates particularly", fill: "#c5b358"},
{source: "18: current product candidates particularly", target: "18: cinacalcet", fill: "#c5b358"},
{source: "18: cinacalcet", target: "18: as well as continue", fill: "#c5b358"},
{source: "18: as well as continue", target: "18: market new product candidates", fill: "#c5b358"},
{source: "18: become profitable", target: "25: future capital", fill: "#3f00ff"},
{source: "25: future capital", target: "25: will depend on", fill: "#3f00ff"},
{source: "25: will depend on", target: "25: enter into collaboration agreements with", fill: "#3f00ff"},
{source: "25: enter into collaboration agreements with", target: "25: proprietary product candidates", fill: "#3f00ff"},
{source: "25: proprietary product candidates", target: "25: collaborators", fill: "#3f00ff"},
{source: "25: collaborators", target: "25: internally funded research development", fill: "#3f00ff"},
{source: "25: internally funded research development", target: "25: commercialization activities", fill: "#3f00ff"},
{source: "25: future capital", target: "26: capital requirements will also depend on", fill: "#8e4585"},
{source: "26: capital requirements will also depend on", target: "26: requirements", fill: "#8e4585"},
{source: "26: requirements", target: "26: activities", fill: "#8e4585"},
{source: "26: activities", target: "26: establish new", fill: "#8e4585"},
{source: "26: establish new", target: "26: collaborations", fill: "#8e4585"},
{source: "26: collaborations", target: "26: collaborators", fill: "#8e4585"},
{source: "26: collaborators", target: "26: contract manufacturers", fill: "#8e4585"},
{source: "26: contract manufacturers", target: "26: commercial supplies", fill: "#8e4585"},
{source: "26: commercial supplies", target: "26: product candidates on", fill: "#8e4585"},
{source: "26: product candidates on", target: "26: sufficient quantities", fill: "#8e4585"},
{source: "26: sufficient quantities", target: "26: technological", fill: "#8e4585"},
{source: "26: technological", target: "26: market developments", fill: "#8e4585"},
{source: "26: market developments", target: "26: regulatory", fill: "#8e4585"},
{source: "26: regulatory", target: "26: commercialize", fill: "#8e4585"},
{source: "26: commercialize", target: "26: future products through", fill: "#8e4585"},
{source: "26: future products through", target: "26: capabilities", fill: "#8e4585"},
{source: "26: capabilities", target: "26: filing prosecuting", fill: "#8e4585"},
{source: "26: filing prosecuting", target: "26: integrating complimentary products technologies", fill: "#8e4585"},
{source: "26: capital requirements will also depend on", target: "45: devote adequate resources", fill: "#69359c"},
{source: "45: devote adequate resources", target: "45: development", fill: "#69359c"},
{source: "45: development", target: "45: PREOS in Europe ", fill: "#69359c"},
{source: "45: PREOS in Europe ", target: "45: PREOS in Europe ", fill: "#69359c"},
{source: "45: PREOS in Europe ", target: "45: profitability will", fill: "#69359c"},
{source: "45: profitability will", target: "45: stock price adversely affected", fill: "#69359c"},
{source: "45: devote adequate resources", target: "START_HERE", fill: "#69359c"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unofficial_collaborator">Unofficial collaborator</a></td>
      <td>An unofficial collaborator or IM (German: [iˈʔɛm] (listen); both from German inoffizieller Mitarbeiter), or euphemistically informal collaborator (informeller Mitarbeiter), was an informant in the German Democratic Republic (East Germany)  who delivered private information to the Ministry for State Security (MfS / Stasi). At the end of the East German government, there was a network of around 189,000 informants, working at every level of society.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pursuit_of_Nazi_collaborators">Pursuit of Nazi collaborators</a></td>
      <td>The pursuit of Nazi collaborators refers to the post-World War II pursuit and apprehension of individuals who were not citizens of the Third Reich at the outbreak of World War II but collaborated with the Nazi regime during the war. Hence, this article does not cover former members of the NSDAP and their fates after the war.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_engineering">Collaborative engineering</a></td>
      <td>Collaborative engineering is defined by the International Journal of Collaborative Engineering as a discipline that "studies the interactive process of engineering collaboration, whereby multiple interested stakeholders resolve conflicts, bargain for individual or collective advantages, agree upon courses of action, and/or attempt to craft joint outcomes which serve their mutual interests."Collaborative engineering is quickly becoming a topic of great interest in recent years due to the explosion of internet technologies. This upsurge is partially due to the success of projects such as Wikipedia and Linux that have proven the efficacy of internet collaboration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborators_(Battlestar_Galactica)">Collaborators (Battlestar Galactica)</a></td>
      <td>"Collaborators"  is the fifth episode of the third season from the science fiction television series Battlestar Galactica.\nThis is the first episode of season 3 to include a survivor count, at 41,435, down considerably from the 49,550 shown in "Lay Down Your Burdens" (Part 2).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_law_to_redeem_pro-Japanese_collaborators'_property">Special law to redeem pro-Japanese collaborators' property</a></td>
      <td>The special law to redeem pro-Japanese collaborators' property (Hanja: 親日反民族行為者財產의國家歸屬에關한特別法, literally "Special Law for the Nationalization of Pro-Japanese Race Traitors' Assets")  is a special South Korean law that passed the South Korean National Assembly on December 8, 2005, and was enacted on December 29, 2005. Under this law, the South Korean government is able to seize land and other properties owned by Korean collaborators (chinilpa), and their descendants, who supported the Japanese administration during the period between 1905 and 1945.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_writing">Collaborative writing</a></td>
      <td>Collaborative writing, or collabwriting is a method of group work that takes place in the workplace and in the classroom. Researchers expand the idea of collaborative writing beyond groups working together to complete a writing task.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_Trials_Directive">Clinical Trials Directive</a></td>
      <td>The Clinical Trials Directive (Officially Directive 2001/20/EC of 4 April 2001, of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use) is a European Union directive that aimed at facilitating the internal market in medicinal products within the European Union, while at the same time maintaining an appropriate level of protection for public health. It seeks to simplify and harmonise the administrative provisions governing clinical trials in the European Community, by establishing a clear, transparent procedure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_state">Regulatory state</a></td>
      <td>The term regulatory state refers to the expansion in the use of rulemaking, monitoring and enforcement techniques and institutions by the state and to a parallel change in the way its positive or negative functions in society are being carried out. The expansion of the state nowadays is generally via regulation and less via taxing and spending.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capture">Regulatory capture</a></td>
      <td>In politics, regulatory capture (also agency capture and client politics) is a form of corruption of authority that occurs when a political entity, policymaker, or regulator is co-opted to serve the commercial, ideological, or political interests of a minor constituency, such as a particular geographic area, industry, profession, or ideological group.When regulatory capture occurs, a special interest is prioritized over the general interests of the public, leading to a net loss for society. The theory of client politics is related to that of rent-seeking and political failure; client politics "occurs when most or all of the benefits of a program go to some single, reasonably small interest (e.g., industry, profession, or locality) but most or all of the costs will be borne by a large number of people (for example, all taxpayers)".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cis-regulatory_element">Cis-regulatory element</a></td>
      <td>Cis-regulatory elements (CREs) or Cis-regulatory modules (CRMs) are regions of non-coding DNA which regulate the transcription of neighboring genes. CREs are vital components of genetic regulatory networks, which in turn control morphogenesis, the development of anatomy, and other aspects of embryonic development, studied in evolutionary developmental biology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_law">Regulatory law</a></td>
      <td>Regulatory law refers to secondary legislation, including regulations, promulgated by an executive branch agency under a delegation from a legislature. It contrasts with statutory law promulgated by the legislative branch, and common law or case law promulgated by the judicial branch.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_technology">Regulatory technology</a></td>
      <td>Regulatory technology, Abrv: regtech, is a new technology that uses information technology to enhance regulatory and compliance processes. Regtech expands across all industries, including: financial services, banking, technology, retail, gaming and healthcare.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NPS PHARMACEUTICALS INC      ITEM 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>The following information <font color="blue">sets forth risk factors</font> that could cause our     actual results to <font color="blue">differ <font color="blue">materially</font> from</font> those contained in forward-looking     statements we have made in this <font color="blue">Annual Report </font>on Form 10-K and those we may     make from time to time</td>
    </tr>
    <tr>
      <td>If any of the <font color="blue"><font color="blue">following risks</font> actually</font> occur, our     business, results of operation, prospects or <font color="blue"><font color="blue">financial condition</font> could</font> be     harmed</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks not presently     known to us, or that we currently deem immaterial, may also affect our     business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">incur net losses</font> and we     may never achieve or maintain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31, 2005, we had an <font color="blue">accumulated deficit</font> of approximately dlra756dtta2     million</td>
    </tr>
    <tr>
      <td>To date, our <font color="blue">sole <font color="blue">revenue from product sales</font></font> has been in the form     of <font color="blue"><font color="blue">royalty payments</font> from</font> Amgen on sales of <font color="blue">cinacalcet</font> HCl</td>
    </tr>
    <tr>
      <td>We have assigned     the right to receive <font color="blue">future <font color="blue">royalties from</font></font> Amgen for sales of <font color="blue">cinacalcet</font> HCl     to a wholly owned subsidiary</td>
    </tr>
    <tr>
      <td>The subsidiary has pledged the right to such     <font color="blue">royalties as security</font> for the repayment of certain notes</td>
    </tr>
    <tr>
      <td>Until such notes,     with a carrying value of dlra175dtta0 million at <font color="blue">December </font>31, 2005, are paid in     full,  all  <font color="blue">royalties from</font> Amgen will go to repay the loan and related     interest and not to us</td>
    </tr>
    <tr>
      <td><font color="blue">If <font color="blue">the Amgen </font></font>royalties are not sufficient to repay     the notes on a <font color="blue">timely basis</font>, or at all, then we may never receive <font color="blue">additional</font>     cash flows from future <font color="blue"><font color="blue">royalty payments</font> from</font> Amgen on sales of <font color="blue">cinacalcet</font>     HCl</td>
    </tr>
    <tr>
      <td>We have not generated any other <font color="blue">revenue from product sales</font> to date, and     it is possible that we will never have <font color="blue">sufficient <font color="blue">product <font color="blue">sales revenue</font></font></font> to     achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We expect to continue to <font color="blue">incur losses</font> for at least     the <font color="blue">next <font color="blue">several years</font> as</font> we and our <font color="blue"><font color="blue">collaborator</font>s</font> and <font color="blue">licensees pursue</font>     <font color="blue">clinical trials</font> and research and <font color="blue"><font color="blue">development</font> efforts</font></td>
    </tr>
    <tr>
      <td>To <font color="blue">become profitable</font>,     we, <font color="blue">either alone</font> or with our <font color="blue"><font color="blue">collaborator</font>s</font> and licensees, must <font color="blue">successfully</font>     develop, <font color="blue">manufacture</font> and market our current <font color="blue">product <font color="blue">candidates</font></font>, <font color="blue">particularly</font>     PREOS^®  and <font color="blue">cinacalcet</font> HCl, <font color="blue">as well as continue</font> to identify, develop,     <font color="blue">manufacture</font> and <font color="blue">market new <font color="blue">product <font color="blue">candidates</font></font></font></td>
    </tr>
    <tr>
      <td>It is possible that we will     never  have  <font color="blue">significant</font>  <font color="blue">product <font color="blue">sales revenue</font></font> or receive <font color="blue">significant</font>     <font color="blue">royalties on</font> our <font color="blue">licensed <font color="blue">product <font color="blue">candidates</font></font></font></td>
    </tr>
    <tr>
      <td>We may require <font color="blue">additional</font> funds</td>
    </tr>
    <tr>
      <td>Currently, we are not a self-sustaining business and <font color="blue">certain economic</font>,     operational and <font color="blue">strategic factors may</font> require us to secure <font color="blue">additional</font> funds</td>
    </tr>
    <tr>
      <td>If we <font color="blue">lack sufficient funding at</font> any time in the future, we may not be able     to  develop  or <font color="blue">commercialize</font> our products, take advantage of business     <font color="blue">opportunities</font> or respond to <font color="blue">competitive pressures</font></td>
    </tr>
    <tr>
      <td>Our current and anticipated <font color="blue">operations</font>, <font color="blue">particularly</font> our <font color="blue">product <font color="blue">development</font></font>     and  <font color="blue">commercialization</font>  programs  <font color="blue">for PREOS</font>^® and teduglutide, require     substantial capital</td>
    </tr>
    <tr>
      <td>We expect that our <font color="blue">existing cash</font> and <font color="blue">cash equivalents</font>     <font color="blue">will sufficiently fund</font> our current and planned <font color="blue">operations</font> through the next     12 months</td>
    </tr>
    <tr>
      <td>However, our <font color="blue">future capital</font> needs <font color="blue">will <font color="blue">depend on</font></font> many factors,     including the extent to which we <font color="blue"><font color="blue">enter into</font> collaboration <font color="blue">agreement</font>s with</font>     respect to any of our <font color="blue"><font color="blue">proprietary</font> <font color="blue">product <font color="blue">candidates</font></font></font>, receive royalty and     milestone  payments  from  our  <font color="blue"><font color="blue">collaborator</font>s</font> and make progress in our     internally funded research, <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">capital <font color="blue"><font color="blue">requirement</font>s</font> will also <font color="blue">depend on</font></font> the magnitude and scope of     these  <font color="blue">activities</font>,  our ability to maintain existing and <font color="blue">establish new</font>     <font color="blue">collaborations</font>,  the terms of those <font color="blue">collaborations</font>, the success of our     <font color="blue"><font color="blue">collaborator</font>s</font> in developing and marketing products under their respective     <font color="blue">collaborations</font>  with  us, the success of our contract <font color="blue">manufacture</font>rs in     producing clinical and <font color="blue">commercial supplies</font> of our <font color="blue"><font color="blue">product <font color="blue">candidates</font></font> on</font> a     timely  basis  and  in <font color="blue">sufficient quantities</font> to meet our <font color="blue"><font color="blue">requirement</font>s</font>,     competing  <font color="blue">technological</font> and <font color="blue">market <font color="blue">development</font>s</font>, the time and cost of     obtaining  <font color="blue">regulatory</font>  approvals,  the  extent  to  which we choose to     <font color="blue">commercialize</font>  our <font color="blue">future products through</font> our own sales and marketing     <font color="blue">capabilities</font>, the cost of preparing, filing, prosecuting, maintaining and     enforcing  patent  and  other  rights and our success in acquiring and     integrating complimentary products, <font color="blue">technologies</font> or companies</td>
    </tr>
    <tr>
      <td>We do not     have <font color="blue">committed external sources</font> of funding, and we <font color="blue">cannot assure</font> you that we     will be able to obtain <font color="blue">additional</font> funds on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>If     <font color="blue">adequate funds</font> are not available, we may be required to:           •   engage in <font color="blue">equity financings</font> that would be dilutive to current     <font color="blue">stockholders</font>;           •   delay, reduce the scope of or <font color="blue">eliminate one</font> or more of our <font color="blue">development</font>     programs;           •   obtain funds through <font color="blue">arrangements</font> with <font color="blue"><font color="blue">collaborator</font>s</font> or others that     may require us to <font color="blue">relinquish rights</font> to <font color="blue">technologies</font>, <font color="blue">product <font color="blue">candidates</font></font> or     products that we <font color="blue">would otherwise seek</font> to develop or <font color="blue">commercialize</font> ourselves;     or           •   <font color="blue">license rights</font> to <font color="blue">technologies</font>, <font color="blue">product <font color="blue">candidates</font></font> or <font color="blue">products on</font>     terms that are less favorable to <font color="blue">us than might otherwise</font> be available</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________       We are <font color="blue"><font color="blue">substantially</font> <font color="blue">dependent on</font></font> our ability to obtain <font color="blue">regulatory</font> approval     to market PREOS^® in the <font color="blue">United States </font>and the ability of Nycomed to obtain     <font color="blue">regulatory</font>  approval to market PREOS^® in Europe</td>
    </tr>
    <tr>
      <td>Our business will be     <font color="blue"><font color="blue">materially</font> harmed</font> and our <font color="blue">stock price may</font> be <font color="blue"><font color="blue">adversely</font> affected</font> if these     <font color="blue">regulatory</font>  approvals  are  not  obtained <font color="blue">with respect</font> to this product     candidate</td>
    </tr>
    <tr>
      <td>In May 2005, we filed an NDA <font color="blue">for PREOS</font>^® with the FDA <font color="blue">seeking approval</font> to     market PREOS^® in the US The PDUFA date <font color="blue">for the PREOS</font>^® NDA is March 10,     2006</td>
    </tr>
    <tr>
      <td>“PDUFA date” refers to the date that the FDA is expected to notify a     drug  sponsor  about the <font color="blue">approval status</font> of an <font color="blue">NDA In March </font>2005, our     <font color="blue">corporate licensee</font>, Nycomed, filed a Marketing Authorization Application, or     MAA, with the European Medicines Agency, or EMEA, <font color="blue">seeking approval</font> to market     PREOS^® in Europe</td>
    </tr>
    <tr>
      <td>The Committee for Medicinal Products for Human Use of the     EMEA, or the CHMP, has adopted a positive <font color="blue">opinion recommending authorization</font>     for  Nycomed  to  market PREOS^® in Europe</td>
    </tr>
    <tr>
      <td>The CHMP <font color="blue">recommendation</font> is     <font color="blue">generally</font> the last step prior to receipt of <font color="blue">marketing authorization by</font> the     EMEA The process of obtaining FDA and other <font color="blue">regulatory</font> approvals is costly,     time consuming, uncertain and subject to <font color="blue">unanticipated delays</font></td>
    </tr>
    <tr>
      <td>In order to     obtain  the  <font color="blue">necessary</font>  <font color="blue">regulatory</font> approvals, we <font color="blue">must <font color="blue">demonstrate</font> with</font>     substantial  evidence  from well-controlled <font color="blue">clinical trials</font> and to the     <font color="blue">satisfaction</font> of the applicable <font color="blue">regulatory</font> reviewing agency that this product     is both safe and <font color="blue">efficacious</font></td>
    </tr>
    <tr>
      <td>We believe the results from the pivotal Phase     III <font color="blue">clinical trial <font color="blue">demonstrate</font>d safety</font> and efficacy <font color="blue">with respect</font> to PREOS^®</td>
    </tr>
    <tr>
      <td>The  most  <font color="blue">frequently</font>  observed  <font color="blue">adverse events across</font> the trials were     hypercalcemia, hypercalciuria and nausea</td>
    </tr>
    <tr>
      <td>However, there is no assurance     that  the <font color="blue">FDA or the EMEA </font>will accept the results of those studies and     determine that the applicable <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> for approval have been     met</td>
    </tr>
    <tr>
      <td>The FDA may require <font color="blue">additional</font> testing for safety and efficacy, which     would result in a substantial delay in the <font color="blue">regulatory</font> approval process for     us</td>
    </tr>
    <tr>
      <td>Additionally, if PREOS^® is approved, the FDA <font color="blue">approved <font color="blue">indication</font></font>, side     effect and <font color="blue">adverse events profile</font>, and product <font color="blue">distribution</font> <font color="blue"><font color="blue">requirement</font>s</font> may     not  be  <font color="blue">competitive with</font> other products and may impede our ability to     <font color="blue"><font color="blue">effective</font>ly promote</font> and <font color="blue">commercialize</font> PREOS^®</td>
    </tr>
    <tr>
      <td>Our <font color="blue">corporate licensee</font>,     Nycomed, has assumed <font color="blue">responsibility</font> for obtaining <font color="blue">regulatory</font> approval to     market PREOS^® in Europe</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on</font> their efforts in this area</td>
    </tr>
    <tr>
      <td>If     we or Nycomed fail to <font color="blue">successfully</font> obtain <font color="blue">regulatory</font> approvals <font color="blue">for PREOS</font>^®,     or face delays, our business will be <font color="blue"><font color="blue">materially</font> harmed</font> and our stock price     may be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We are entirely <font color="blue">dependent on</font> the efforts of Nycomed to develop and market     PREOS^® in Europe</td>
    </tr>
    <tr>
      <td>If Nycomed does not <font color="blue">devote adequate resources</font> to the     <font color="blue">development</font>  and  marketing  of PREOS^® in Europe or if Nycomed is not     successful in its efforts, our sales of PREOS^® in Europe will be reduced,     our <font color="blue">profitability</font> will be delayed and our stock price <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Nycomed has also assumed <font color="blue">responsibility</font> to obtain     <font color="blue">regulatory</font> approval to market PREOS^® in Europe</td>
    </tr>
    <tr>
      <td>If Nycomed is not able to     obtain <font color="blue">regulatory</font> approval to market PREOS^® in Europe in a <font color="blue">timely manner</font> or     at all, or if it does not <font color="blue">devote adequate resources</font> to the <font color="blue">development</font> and     marketing  of PREOS^® in Europe then European sales of PREOS^® will be     negatively impacted which will <font color="blue">adversely</font> affect our <font color="blue">profitability</font> and stock     price</td>
    </tr>
    <tr>
      <td>We  may never develop any more <font color="blue">commercial drugs</font> or other products that     <font color="blue">generate revenues</font></td>
    </tr>
    <tr>
      <td><font color="blue">Cinacalcet HCl </font>is our only drug, to date, that is <font color="blue"><font color="blue">generating</font> revenues</font></td>
    </tr>
    <tr>
      <td>Our     remaining  product  <font color="blue">candidates</font>  will  require  <font color="blue">significant</font>  <font color="blue">additional</font>     <font color="blue">development</font>,  clinical  trials,  <font color="blue">regulatory</font>  <font color="blue">clearances</font> and <font color="blue">additional</font>     <font color="blue">investment</font>  before they can be <font color="blue">commercialize</font>d</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">development</font></font>     <font color="blue">efforts may</font> not lead to <font color="blue">commercial drugs</font> for a number of reasons, including     the failure of our <font color="blue">product <font color="blue">candidates</font></font> to be safe and <font color="blue">effective</font> in clinical     trials or because we have inadequate financial or other resources to pursue     the <font color="blue">programs through</font> the <font color="blue">clinical trial process</font></td>
    </tr>
    <tr>
      <td>Even if we are able to     <font color="blue">commercialize</font> one or more of our <font color="blue">product <font color="blue">candidates</font></font>, we <font color="blue">cannot assure</font> you     that such <font color="blue">product <font color="blue">candidates</font></font> will find acceptance in the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>We have no internal <font color="blue">manufacturing</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>We <font color="blue"><font color="blue">depend on</font> <font color="blue">third parties</font></font>,     including a number of <font color="blue">sole suppliers</font>, for <font color="blue">manufacturing</font>, supply, and storage     of  our <font color="blue">product <font color="blue">candidates</font></font> to be used for <font color="blue">commercial launch</font> and in our     <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue"><font color="blue">introduction</font>s may</font> be delayed or suspended if the     <font color="blue">manufacture</font> or supply of our products is <font color="blue">interrupted</font> or <font color="blue">discontinued</font></td>
    </tr>
    <tr>
      <td>We do not have internal <font color="blue">manufacturing</font> <font color="blue">capabilities</font> to produce supplies of     PREOS^®, teduglutide or any of our other <font color="blue">product <font color="blue">candidates</font></font> to support     clinical  trials  or  <font color="blue">commercial launch</font> of these products, if they are     approved</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on</font> <font color="blue">third parties</font> for <font color="blue">manufacturing</font>, supply, and     storage  of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If we are unable to contract for a     <font color="blue">sufficient supply</font> of our <font color="blue"><font color="blue">product <font color="blue">candidates</font></font> on</font> acceptable terms, or if we     <font color="blue">encounter delays</font> or <font color="blue"><font color="blue">difficult</font>ies</font> in the <font color="blue">manufacturing</font> or <font color="blue">supply process</font> or     our <font color="blue"><font color="blue"><font color="blue">relationship</font>s</font> with</font> our <font color="blue">manufacture</font>rs, we may not have <font color="blue">sufficient product</font>     to conduct or complete our <font color="blue">clinical trials</font> or <font color="blue">support preparations</font> for the     <font color="blue">commercial launch</font> of our <font color="blue">product <font color="blue">candidates</font></font>, if approved</td>
    </tr>
    <tr>
      <td>We have <font color="blue"><font color="blue">entered into</font> <font color="blue">agreement</font>s with</font> contract <font color="blue">manufacture</font>rs to <font color="blue">manufacture</font>     clinical and <font color="blue">commercial supplies</font> of PREOS^® and the <font color="blue">injection pen</font> device     used to <font color="blue">administer</font> PREOS^®</td>
    </tr>
    <tr>
      <td>These contract <font color="blue">manufacture</font>rs are our only source     for the production of PREOS^® and the pen</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> a number of contract <font color="blue">manufacture</font>rs to <font color="blue">supply key components</font> of     PREOS^®</td>
    </tr>
    <tr>
      <td>For instance, we have <font color="blue"><font color="blue">entered into</font> <font color="blue">agreement</font>s with</font> SynCo Bio     Partners BV, or SynCo, and Boehringer Ingelheim Austria GmbH, or BI, to                                           20     ______________________________________________________________________       produce bulk supplies of the <font color="blue">active <font color="blue">pharmaceutical</font></font> ingredient of PREOS^®</td>
    </tr>
    <tr>
      <td>Historically, SynCo has supplied the <font color="blue">bulk drug product</font> for our clinical     <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>Some of the <font color="blue">bulk drug product</font> <font color="blue">manufacture</font>d by SynCo will be     used in the <font color="blue">commercial launch</font> of PREOS^® if approved</td>
    </tr>
    <tr>
      <td>BI <font color="blue">will supply</font> the     bulk  drug  product for our commercial <font color="blue"><font color="blue">requirement</font>s</font>, which include the     <font color="blue">commercial launch</font> of PREOS^®, when and if approved</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">technology</font> utilized</font>     by SynCo to produce the <font color="blue">active <font color="blue">pharmaceutical</font></font> ingredient of PREOS^® has been     transferred to BI and our <font color="blue">agreement</font> with SynCo has expired</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection</font>     with the <font color="blue"><font color="blue">technology</font> transfer</font>, we are required to establish for <font color="blue">regulatory</font>     <font color="blue">purposes <font color="blue">comparability</font> between</font> the finished <font color="blue">drug product supplied by</font> <font color="blue">SynCo     </font>in the conduct of our <font color="blue">clinical trials</font> and the <font color="blue">commercial supplies</font> of the     finished <font color="blue">drug product supplied by</font> BI We believe that we established the     required <font color="blue">comparability</font> in our NDA filing</td>
    </tr>
    <tr>
      <td>BI has <font color="blue">successfully</font> completed     initial <font color="blue">manufacturing</font> runs of the commercial <font color="blue">bulk drug product</font> and we expect     BI to be able to produce sufficient bulk supplies of PREOS^® on a timely     basis</td>
    </tr>
    <tr>
      <td>Nevertheless, <font color="blue">manufacturing</font> biological products is complex and no     assurances  can be provided that BI will be able to produce commercial     quantities of <font color="blue">bulk drug product</font> in a <font color="blue">timely manner</font> or at all</td>
    </tr>
    <tr>
      <td>We  also  depend  on  Vetter Pharma-Fertigung GmbH, or Vetter, for the     production of finished supplies of PREOS^®</td>
    </tr>
    <tr>
      <td>Because the “fill and finish”     aspect  of  the  <font color="blue">manufacturing</font> process <font color="blue">for PREOS</font>^® requires the use of     Vetter’s <font color="blue"><font color="blue">proprietary</font> <font color="blue">technology</font></font>, Vetter is our sole source for finished     supplies of PREOS^®</td>
    </tr>
    <tr>
      <td>Absent the <font color="blue">development</font> of an <font color="blue">alternative method</font> of     delivery  of  PREOS^®, we will remain <font color="blue">dependent on</font> the <font color="blue">availability</font> of     Vetter’s <font color="blue"><font color="blue">proprietary</font> <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>Vetter has only produced small quantities     of finished supplies of PREOS^® to date, but has commenced <font color="blue">manufacturing</font>     <font color="blue">commercial quantities</font> of finished supplies of PREOS^®</td>
    </tr>
    <tr>
      <td>We expect Vetter to     be able to meet our commercial supply needs <font color="blue">for PREOS</font>^®</td>
    </tr>
    <tr>
      <td>Nevertheless, the     fill and finish aspect of the <font color="blue">manufacturing</font> process <font color="blue">for PREOS</font>^® is complex     and  <font color="blue">no assurances</font> can be provided that Vetter will be able to produce     <font color="blue">commercial quantities</font> of finished supplies of PREOS^® in a <font color="blue">timely manner</font> or     at all</td>
    </tr>
    <tr>
      <td>We rely on Ypsomed AG, or Ypsomed, to <font color="blue">manufacture</font> the pen used for the     <font color="blue">administration</font> of PREOS^®</td>
    </tr>
    <tr>
      <td>Ypsomed is our sole source for the pen and,     absent the <font color="blue">development</font> of an <font color="blue">alternative method</font> of delivery of PREOS^®, we     will remain <font color="blue">dependent on</font> Ypsomed’s <font color="blue">technology</font> to produce the pen</td>
    </tr>
    <tr>
      <td>The pen     has <font color="blue">been specifically designed</font> and developed for delivery of PREOS^®</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>will be the first time that Ypsomed will have produced <font color="blue">commercial quantities</font>     of the pen</td>
    </tr>
    <tr>
      <td>To date, Ypsomed has not produced <font color="blue">commercial quantities</font> of the     pen, but has <font color="blue">commenced commercial production</font> of the pen</td>
    </tr>
    <tr>
      <td>We expect Ypsomed     to be able to produce sufficient supplies of the pen on a <font color="blue">timely basis</font> to     support the <font color="blue">commercial launch</font> of PREOS^®, when and if <font color="blue">approved by</font> the FDA     Nevertheless, <font color="blue">manufacturing</font> drug delivery devices such as the pen is complex     and <font color="blue">no assurances</font> can be provided that Ypsomed will be able to produce     <font color="blue">commercial quantities</font> of the pen in a <font color="blue">timely manner</font> or at all</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">various risks</font> when <font color="blue">relying on</font> our contract <font color="blue">manufacture</font>rs     for the supply of PREOS^® and the pen</td>
    </tr>
    <tr>
      <td>If, for example, Vetter is unable to     produce finished supplies of PREOS^® in required quantities or in <font color="blue">accordance</font>     with  our required <font color="blue">specifications</font>, in a <font color="blue">timely manner</font> or at all, or if     Ypsomed  is  unable  to  produce the pen in required quantities and in     <font color="blue">accordance</font> with our required <font color="blue">specifications</font>, in a <font color="blue">timely manner</font> or at all,     the <font color="blue">commercial launch</font> of PREOS^® would be delayed and we could be forced to     ultimately develop an <font color="blue">alternative delivery process</font> <font color="blue">for PREOS</font>^®, <font color="blue">which would</font>     require  <font color="blue">additional</font>  <font color="blue">clinical trials</font> and <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>We have     experienced <font color="blue">certain instances</font> where our contract <font color="blue">manufacture</font>rs have produced     product that has not met our required <font color="blue">specifications</font> and could not be used     in <font color="blue">clinical trials</font> or for <font color="blue">commercial launch</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">extended disruption</font> or     <font color="blue">termination</font> of our <font color="blue"><font color="blue">relationship</font> with</font> any of our contract <font color="blue">manufacture</font>rs for     PREOS^® would <font color="blue">materially</font> harm our business and <font color="blue">financial condition</font> and could     <font color="blue">adversely</font> impact our stock price</td>
    </tr>
    <tr>
      <td>We also have <font color="blue">arrangements</font> with contract <font color="blue">manufacture</font>rs for <font color="blue">clinical supplies</font>     of  teduglutide</td>
    </tr>
    <tr>
      <td>If  clinical  supplies of teduglutide are disrupted,     exhausted, or fail to arrive when needed, we will have to <font color="blue">substantially</font>     curtail or <font color="blue">postpone initiation</font> of planned <font color="blue">clinical trials</font> with those product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">Dependence </font>on contract <font color="blue">manufacture</font>rs for <font color="blue">commercial production involves</font> a     number of <font color="blue">additional</font> risks, many of which are outside our control</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">additional</font> risks include:           •   there may be delays in scale-up to quantities needed for clinical     trials and <font color="blue">commercial launch</font> or failure to <font color="blue">manufacture</font> such quantities to     our <font color="blue">specifications</font>, or to deliver <font color="blue">such quantities on</font> the dates we require;           •   our current and future <font color="blue">manufacture</font>rs are subject to ongoing, periodic,     <font color="blue">unannounced inspection by</font> the FDA and <font color="blue">corresponding</font> state and <font color="blue">international</font>     <font color="blue">regulatory</font> <font color="blue">authorities</font> for compliance with strictly enforced cGMP     <font color="blue">regulations</font> and similar foreign standards, and we do not have control over     our contract <font color="blue">manufacture</font>rs’ compliance with these <font color="blue">regulations</font> and standards;           •   our current and future <font color="blue">manufacture</font>rs may not be able to <font color="blue">comply with</font>     applicable <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font>, <font color="blue">which would</font> prohibit them from     <font color="blue">manufacturing</font> products for us;           •   if we need to change to other commercial <font color="blue">manufacturing</font> <font color="blue">contractors</font>,     the FDA and comparable foreign <font color="blue">regulators</font> must approve these <font color="blue">contractors</font>     prior to our use, <font color="blue">which would</font> require new testing and compliance     <font color="blue">inspections</font>, and the new <font color="blue">manufacture</font>rs would have to be educated in, or     <font color="blue">themselves</font> develop <font color="blue">substantially</font> equivalent processes <font color="blue">necessary</font> for, the     production of our products;           •   our <font color="blue">manufacture</font>rs might not be able to fulfill our commercial needs,     <font color="blue">which would</font> require us to seek new <font color="blue">manufacturing</font> <font color="blue">arrangements</font> and may result     in substantial delays in <font color="blue">meeting market demand</font>; and           •   we may not have <font color="blue"><font color="blue">intellectual</font> property rights</font>, or may have to share     <font color="blue"><font color="blue">intellectual</font> property rights</font>, to any <font color="blue">improvements</font> in the <font color="blue">manufacturing</font>     processes or new <font color="blue">manufacturing</font> processes for our products</td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________       Any of these factors could cause us to delay or suspend <font color="blue">clinical trials</font>,     <font color="blue">regulatory</font>  submission, required approvals or <font color="blue">commercialization</font> of our     products under <font color="blue">development</font>, entail higher costs and result in our being     unable to <font color="blue">effective</font>ly <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>We do not <font color="blue">currently intend</font> to <font color="blue">manufacture</font> any of our <font color="blue">product <font color="blue">candidates</font></font>,     although we may choose to do so in the future</td>
    </tr>
    <tr>
      <td>If we decide to <font color="blue">manufacture</font>     our products, we would be subject to the <font color="blue">regulatory</font> risks and <font color="blue"><font color="blue">requirement</font>s</font>     described above</td>
    </tr>
    <tr>
      <td>We would also be subject to similar risks regarding delays     or <font color="blue"><font color="blue">difficult</font>ies</font> encountered in <font color="blue">manufacturing</font> our <font color="blue">pharmaceutical</font> products and     we would require <font color="blue">additional</font> facilities and substantial <font color="blue">additional</font> capital</td>
    </tr>
    <tr>
      <td>We  cannot  assure you that we would be able to <font color="blue">manufacture</font> any of our     products <font color="blue">successfully</font> in <font color="blue">accordance</font> with <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> and in a     cost-<font color="blue">effective</font> manner</td>
    </tr>
    <tr>
      <td>Clinical trials are long, expensive and <font color="blue">uncertain processes</font> and the FDA may     ultimately not approve any of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you     that <font color="blue">data collected from preclinical</font> and <font color="blue">clinical trials</font> of our product     <font color="blue">candidates</font> will be sufficient to <font color="blue">support approval by</font> the FDA, the failure of     <font color="blue">which could</font> delay our <font color="blue">profitability</font> and <font color="blue">adversely</font> affect our stock price</td>
    </tr>
    <tr>
      <td>Before we receive <font color="blue">regulatory</font> approval for the <font color="blue">commercial sale</font> of our product     <font color="blue">candidates</font>, our <font color="blue">product <font color="blue">candidates</font></font> are subject to extensive pre-clinical     testing  and <font color="blue">clinical trials</font> to <font color="blue">demonstrate</font> their safety and efficacy</td>
    </tr>
    <tr>
      <td>Clinical trials are long, expensive and <font color="blue">uncertain processes</font></td>
    </tr>
    <tr>
      <td>Clinical trials     may  not  be  commenced  or completed on schedule, and the FDA may not     <font color="blue">ultimately approve</font> our <font color="blue">product <font color="blue">candidates</font></font> for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>Further, even     if the results of our <font color="blue">preclinical studies</font> or <font color="blue">clinical trials</font> are initially     positive, it is possible that we will obtain <font color="blue">different</font> results in the later     stages of drug <font color="blue">development</font> or that results seen in <font color="blue">clinical trials</font> will not     continue  with longer-term treatment</td>
    </tr>
    <tr>
      <td>Drugs in late stages of clinical     <font color="blue">development</font> may fail to show the desired safety and efficacy traits despite     having progressed through initial <font color="blue">clinical testing</font></td>
    </tr>
    <tr>
      <td>For example, positive     results in early <font color="blue">Phase I or Phase II </font><font color="blue">clinical trials</font> may not be repeated in     larger <font color="blue">Phase II or Phase III </font><font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>All of our potential drug     <font color="blue">candidates</font> are prone to the risks of <font color="blue">failure inherent</font> in drug <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical trials</font> of any of our drug <font color="blue">candidates</font>, including teduglutide,     could be <font color="blue">unsuccessful</font>, <font color="blue">which would</font> prevent us from <font color="blue">commercializing</font> the drug</td>
    </tr>
    <tr>
      <td>Our failure to develop safe, commercially viable drugs would <font color="blue">substantially</font>     impair our ability to <font color="blue">generate revenues</font> and sustain our <font color="blue">operations</font> and would     <font color="blue">materially</font> harm our business and <font color="blue">adversely</font> affect our stock price</td>
    </tr>
    <tr>
      <td>If  we  fail  to  maintain our existing or <font color="blue">establish new</font> collaborative     <font color="blue"><font color="blue">relationship</font>s</font>, or if our <font color="blue"><font color="blue">collaborator</font>s</font> do not <font color="blue">devote adequate resources</font> to     the <font color="blue">development</font> and <font color="blue">commercialization</font> of our licensed drug <font color="blue">candidates</font>, we     may have to reduce our rate of <font color="blue">product <font color="blue">development</font></font> and may not see products     brought to market or be able to achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our strategy for developing, <font color="blue">manufacturing</font> and <font color="blue">commercializing</font> our products     includes entering into various <font color="blue"><font color="blue"><font color="blue">relationship</font>s</font> with</font> other <font color="blue">pharmaceutical</font>     companies  to  advance many of our programs</td>
    </tr>
    <tr>
      <td>We have <font color="blue">granted exclusive</font>     <font color="blue">development</font>, <font color="blue">commercialization</font> and <font color="blue">marketing rights</font> to a number of our     <font color="blue"><font color="blue">collaborator</font>s</font> for some of our key <font color="blue">product <font color="blue">development</font></font> programs, including     <font color="blue">cinacalcet</font>  HCl,  PREOS^®,  <font color="blue">calcilytics</font>,  mGluRs  and <font color="blue">glycine reuptake</font>     <font color="blue">inhibitors</font></td>
    </tr>
    <tr>
      <td>Except in the case of our <font color="blue">collaboration with</font> <font color="blue">AstraZeneca </font>for     research involving mGluRs, our <font color="blue"><font color="blue">collaborator</font>s</font> have full control over those     efforts in their <font color="blue">territories</font> and the resources they commit to the programs</td>
    </tr>
    <tr>
      <td>Accordingly, the success of the <font color="blue">development</font> and <font color="blue">commercialization</font> of product     <font color="blue">candidates</font> in those <font color="blue">programs depends on</font> their efforts and is beyond our     control</td>
    </tr>
    <tr>
      <td>For us to receive any <font color="blue">significant</font> milestone or <font color="blue">royalty payments</font>     from our <font color="blue"><font color="blue">collaborator</font>s</font>, they must advance drugs through <font color="blue">clinical trials</font>,     establish the safety and efficacy of our drug <font color="blue">candidates</font>, obtain <font color="blue">regulatory</font>     approvals and achieve <font color="blue">market acceptance</font> of those products</td>
    </tr>
    <tr>
      <td>As a result, if a     <font color="blue">collaborator</font> elects to terminate its <font color="blue">agreement</font> with us <font color="blue">with respect</font> to a     <font color="blue">research program</font>, our ability to advance the <font color="blue">program may</font> be <font color="blue">significant</font>ly     impaired or we may elect to <font color="blue">discontinue funding</font> the <font color="blue">program altogether</font></td>
    </tr>
    <tr>
      <td>Under our <font color="blue">agreement</font> with AstraZeneca, we are required to co-direct the     research and to pay for an equal share of the <font color="blue">preclinical research costs</font>,     including capital and a minimum number of <font color="blue">personnel through</font> March 2009</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">commitment</font> of personnel and <font color="blue">capital may limit</font> or restrict our ability to     initiate or pursue other <font color="blue">research efforts</font></td>
    </tr>
    <tr>
      <td>As  part of our <font color="blue">product <font color="blue">development</font></font> and <font color="blue">commercialization</font> strategy, we     <font color="blue">evaluate whether</font> to seek <font color="blue"><font color="blue">collaborator</font>s</font> for our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If we     elect  to  <font color="blue">collaborate</font>,  we may not be able to <font color="blue">negotiate collaborative</font>     <font color="blue">arrangements</font> for our <font color="blue"><font color="blue">product <font color="blue">candidates</font></font> on</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>If     we are unable to establish collaborative <font color="blue">arrangements</font>, we will either need     to  increase  our  <font color="blue">expenditures</font>  and  undertake  the  <font color="blue">development</font>  and     <font color="blue">commercialization</font> <font color="blue">activities</font> at our own expense or delay further <font color="blue">development</font>     of the <font color="blue">affected <font color="blue">product candidate</font></font></td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________       <font color="blue">Collaborative </font><font color="blue">agreement</font>s, including our existing collaborative <font color="blue">agreement</font>s,     pose the <font color="blue">following risks</font>:           •   our <font color="blue">contracts with</font> <font color="blue"><font color="blue">collaborator</font>s</font> may be terminated and we may not be     able to replace our <font color="blue"><font color="blue">collaborator</font>s</font>;           •   the terms of our <font color="blue">contracts with</font> our <font color="blue"><font color="blue">collaborator</font>s</font> may not be favorable     to us in the future;           •   our <font color="blue"><font color="blue">collaborator</font>s</font> may not pursue further <font color="blue">development</font> and     <font color="blue">commercialization</font> of compounds resulting from their <font color="blue">collaborations</font> with us;           •   a <font color="blue">collaborator</font> with marketing and <font color="blue">distribution</font> rights to one or more     of our <font color="blue">product <font color="blue">candidates</font></font> may not <font color="blue">commit enough resources</font> to the marketing     and <font color="blue">distribution</font> of such <font color="blue">candidates</font>;           •   <font color="blue">disputes with</font> our <font color="blue"><font color="blue">collaborator</font>s</font> may arise, leading to delays in or     <font color="blue">termination</font> of the research, <font color="blue">development</font> or <font color="blue">commercialization</font> of our product     <font color="blue">candidates</font>, or resulting in <font color="blue">significant</font> litigation or <font color="blue">arbitration</font>;           •   <font color="blue">contracts with</font> our <font color="blue"><font color="blue">collaborator</font>s</font> may fail to provide <font color="blue">significant</font>     protection if one or more of them fail to perform;           •   in some <font color="blue">circumstances</font>, if a <font color="blue">collaborator</font> terminates an <font color="blue">agreement</font>, or     if we are found to be in breach of our <font color="blue">obligations</font>, we may be unable to     secure all of the <font color="blue">necessary</font> <font color="blue"><font color="blue">intellectual</font> property rights</font> and <font color="blue">regulatory</font>     approval to continue developing the <font color="blue">same compound</font> or product;           •   our <font color="blue"><font color="blue">collaborator</font>s</font> could independently develop, or develop with third     parties, drugs that <font color="blue">compete with</font> our products; and           •   we may be unable to meet our financial or other <font color="blue">obligations</font> under our     collaborative <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you of the success of our <font color="blue">current collaborative efforts nor</font>     can we assure you of the success of any of our <font color="blue">future collaborative efforts</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">collaborative efforts fail</font>, our business and <font color="blue">financial condition</font>     would be <font color="blue"><font color="blue">materially</font> harmed</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">agreement</font> with Allergan to promote Restasis^® is <font color="blue">unsuccessful</font> or     <font color="blue">terminated prior</font> to the expiration of its <font color="blue">initial term</font>, our <font color="blue">profitability</font>     under the <font color="blue">agreement</font> may be <font color="blue">adversely</font> impacted and our efforts to further     develop and maintain our <font color="blue"><font color="blue">sales force</font> prior</font> to the <font color="blue">commercial launch</font> of     PREOS^® may be delayed</td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into</font> an <font color="blue">agreement</font> with Allergan to promote Allergan’s FDA     <font color="blue">approved drug</font> Restasis^®</td>
    </tr>
    <tr>
      <td>Allergan <font color="blue">may terminate</font> the <font color="blue">agreement</font> on our breach     or on the occurrence of other events</td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in promoting     Restasis^® or if the <font color="blue">agreement</font> is <font color="blue">terminated prior</font> to the expiration of its     <font color="blue">initial term</font> our expected <font color="blue">revenues from</font> our <font color="blue">promotional efforts will</font> be     reduced  and  we  may have to bear the cost of our <font color="blue"><font color="blue">sales force</font> with no</font>     <font color="blue">corresponding</font> revenue</td>
    </tr>
    <tr>
      <td>Additionally, we expect that our efforts to promote     Restasis^® <font color="blue">will assist</font> in the further <font color="blue">development</font> of a <font color="blue">sales force</font> to launch     PREOS^®, if approved</td>
    </tr>
    <tr>
      <td>Should any of these events occur prior to the approval     of PREOS^®, our <font color="blue">sales force</font> would not have any product to <font color="blue">promote which</font>     would make it <font color="blue">difficult</font> to maintain the <font color="blue">current size</font> of our <font color="blue">sales force</font>, the     <font color="blue">development</font> of our <font color="blue">sales force</font> may be <font color="blue">adversely</font> impacted and as a result our     <font color="blue">profitability</font> may be delayed and our stock price <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Because we have never marketed, sold or <font color="blue">distributed</font> a product, we may be     unable to <font color="blue">successfully</font> market and sell our products and <font color="blue">generate revenues</font></td>
    </tr>
    <tr>
      <td>We have recruited and continue to recruit sales, marketing, market research     and product planning personnel</td>
    </tr>
    <tr>
      <td>However, we still require <font color="blue">additional</font> sales,     marketing and <font color="blue">distribution</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>In order to <font color="blue">commercialize</font> any     <font color="blue">product <font color="blue">candidates</font></font> for which we receive FDA approval, we <font color="blue">must rely on</font> our     sales  and  marketing  force or <font color="blue">rely on <font color="blue">third parties</font></font> to perform these     functions</td>
    </tr>
    <tr>
      <td>To <font color="blue">market products directly</font>, our marketing and <font color="blue">sales force</font> must     have  technical  expertise and supporting <font color="blue">distribution</font> capability</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">inability</font> to continue to develop expertise and <font color="blue">attract skilled marketing</font> and     sales personnel to our sales and <font color="blue">distribution</font> <font color="blue">capabilities</font> may limit our     ability to gain <font color="blue">market acceptance</font> for our products and <font color="blue">generate revenues</font></td>
    </tr>
    <tr>
      <td>We     have <font color="blue">entered into</font> an <font color="blue">agreement</font> with Ventiv Pharma Services, or Ventiv, to     assist  in  the <font color="blue">development</font> of a <font color="blue">sales force</font> to promote Restasis^® and     Kineret^®  under our respective <font color="blue">agreement</font>s with <font color="blue">Allergan and Amgen</font></td>
    </tr>
    <tr>
      <td>We     believe that our <font color="blue">promotional efforts with</font> Restasis^® and Kineret^® and our     <font color="blue"><font color="blue">relationship</font> with</font> Ventiv have <font color="blue">accelerated</font> our creation of a <font color="blue">sales force</font> to     promote  PREOS^®</td>
    </tr>
    <tr>
      <td>We  cannot  assure you that our <font color="blue">sales force</font> will be     successful in <font color="blue">generating</font> PREOS <font color="blue">sales revenue</font> in a <font color="blue">highly competitive market</font></td>
    </tr>
    <tr>
      <td>Further, if we establish <font color="blue"><font color="blue"><font color="blue">relationship</font>s</font> with</font> one or more <font color="blue">companies with</font>     existing <font color="blue">distribution</font> systems and direct <font color="blue">sales force</font>s to market any or all     of our <font color="blue">product <font color="blue">candidates</font></font>, we <font color="blue">cannot assure</font> you that we will be able to     <font color="blue">enter into</font> or maintain <font color="blue">agreement</font>s with these <font color="blue">companies on</font> acceptable terms,     if at all</td>
    </tr>
    <tr>
      <td>In addition, we have incurred <font color="blue">significant</font> expenses in developing sales,     marketing and <font color="blue">distribution</font> <font color="blue">capabilities</font> in <font color="blue">connection</font> with determining     potential  <font color="blue">commercialization</font>  strategies  <font color="blue">with respect</font> to PREOS^®</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">commercialization</font>  strategy  <font color="blue">with respect</font> to PREOS^® and other product     <font color="blue">candidates</font> <font color="blue">will <font color="blue">depend on</font></font> a number of factors, including:           •   the extent to which we are successful in <font color="blue">securing collaborative</font>     partners to offset some or all of the funding <font color="blue">obligations</font> <font color="blue">with respect</font> to     other <font color="blue">product <font color="blue">candidates</font></font>;                                           23     ______________________________________________________________________         •   whether we are able to establish <font color="blue">agreement</font>s with <font color="blue">third party</font>     <font color="blue"><font color="blue">collaborator</font>s</font> <font color="blue">with respect</font> to any of our <font color="blue"><font color="blue">product <font color="blue">candidates</font></font> on</font> terms that     are acceptable to us;           •   the extent to which our <font color="blue">agreement</font> with our <font color="blue"><font color="blue">collaborator</font>s</font> permits us to     <font color="blue">exercise marketing</font> or promotion rights <font color="blue">with respect</font> to the product     candidate; and           •   how our <font color="blue">product <font color="blue">candidates</font></font> compare to <font color="blue">competitive products with</font>     respect to labeling, pricing, <font color="blue">therapeutic</font> effect and method of delivery</td>
    </tr>
    <tr>
      <td>A number of these factors are outside of our control and will be <font color="blue">difficult</font>     to determine</td>
    </tr>
    <tr>
      <td>Therefore, we may change <font color="blue">commercialization</font> strategies by     entering into <font color="blue">agreement</font>s with our <font color="blue"><font color="blue">collaborator</font>s</font> or <font color="blue">third parties</font> after we     have incurred <font color="blue">significant</font> expenses in developing internal sales, marketing     and <font color="blue">distribution</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>A change of this nature could result in     <font color="blue">increased expenses</font> or delays in <font color="blue">commercialization</font> and <font color="blue">therefore <font color="blue">could delay</font></font>     revenues and <font color="blue">adversely</font> affect our future operating results</td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">uncertainty</font> of <font color="blue">pharmaceutical</font> pricing, <font color="blue">reimbursement</font> and     healthcare  reform  measures,  we  may  be unable to sell our products     profitably</td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> of <font color="blue"><font color="blue">reimbursement</font> by <font color="blue">governmental</font></font> and other third-party     <font color="blue">payors affects</font> the market for any <font color="blue">pharmaceutical</font> product</td>
    </tr>
    <tr>
      <td>These third-party     <font color="blue">payors continually attempt</font> to contain or reduce the costs of healthcare</td>
    </tr>
    <tr>
      <td>There have been a number of <font color="blue">legislative</font> and <font color="blue">regulatory</font> proposals to change     the <font color="blue">healthcare system</font> and <font color="blue">further proposals</font> are likely</td>
    </tr>
    <tr>
      <td>Medicare’s policies     may decrease the market for our products that are designed to <font color="blue">treat patients</font>     with age-related disorders, such as <font color="blue">osteoporosis</font> and <font color="blue">hyperparathyroidism</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">uncertainty</font> exists <font color="blue">with respect</font> to the <font color="blue"><font color="blue">reimbursement</font> status</font> of     <font color="blue">newly approved healthcare products</font></td>
    </tr>
    <tr>
      <td>In addition, third-party payors are <font color="blue">increasingly challenging</font> the price and     cost-<font color="blue">effective</font>ness of <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>We might not be able to     sell  our <font color="blue">products profitably</font> or recoup the value of our <font color="blue">investment</font> in     <font color="blue">product <font color="blue">development</font></font> if <font color="blue">reimbursement</font> is unavailable or limited in scope,     <font color="blue">particularly</font> for <font color="blue">product <font color="blue">candidates</font></font> addressing small <font color="blue">patient populations</font>,     <font color="blue">such as teduglutide</font> for the treatment of short <font color="blue">bowel syndrome</font></td>
    </tr>
    <tr>
      <td>The passage of the Medicare Prescription Drug and Modernization Act of 2003,     or the MMA, imposes new <font color="blue"><font color="blue">requirement</font>s</font> for the <font color="blue">distribution</font> and pricing of     <font color="blue">prescription drugs</font> for Medicare <font color="blue"><font color="blue">beneficiaries</font> which may affect</font> the marketing     of our products</td>
    </tr>
    <tr>
      <td>The MMA <font color="blue">also introduced</font> a new <font color="blue">reimbursement</font> methodology,     part of <font color="blue">which went into</font> effect in 2004</td>
    </tr>
    <tr>
      <td>At this point, it is not clear what     effect the MMA will have <font color="blue">on prices paid</font> for currently <font color="blue">approved drug</font>s and the     <font color="blue">pricing options</font> for <font color="blue">new drugs approved</font> after January 1, 2006</td>
    </tr>
    <tr>
      <td>Moreover,     while the MMA <font color="blue">applies only</font> to <font color="blue">drug benefits</font> for Medicare <font color="blue">beneficiaries</font>,     <font color="blue">private payors often follow</font> Medicare <font color="blue">coverage policy</font> and <font color="blue">payment limitations</font>     in setting their own <font color="blue">payment rates</font></td>
    </tr>
    <tr>
      <td>Any reduction in payment that results     from  the  MMA  may  result  in  a  similar reduction in <font color="blue">payments from</font>     non-<font color="blue">governmental</font> payors</td>
    </tr>
    <tr>
      <td>In addition, in some foreign countries, the <font color="blue">proposed pricing</font> for a drug must     be approves before it may be <font color="blue">lawfully marketed</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">requirement</font>s</font> governing     <font color="blue">drug pricing vary widely from country</font> to country</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">there will</font>     continue  to  be  a number of federal and state proposals to implement     <font color="blue">governmental</font>  pricing  controls</td>
    </tr>
    <tr>
      <td>While we <font color="blue">cannot predict whether such</font>     <font color="blue">legislative</font> or <font color="blue">regulatory</font> proposals will be adopted, the adoption of such     <font color="blue">proposals could</font> have a material adverse effect on our business, financial     condition and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>As  a  result  of  intense <font color="blue">competition</font> and <font color="blue">technological</font> change in the     <font color="blue">pharmaceutical</font> industry, the <font color="blue">marketplace may</font> not accept our products, and we     may not be able to compete <font color="blue">successfully</font> against other companies in our     industry and achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> industries are <font color="blue">intensely competitive</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue"><font color="blue">competitors</font> both</font> in the US and <font color="blue">international</font>ly including major     multi-national  <font color="blue">pharmaceutical</font>  companies, chemical companies, biotech     companies,  <font color="blue">universities</font> and other <font color="blue">research <font color="blue">organizations</font></font></td>
    </tr>
    <tr>
      <td>Many of our     <font color="blue">competitors</font> have <font color="blue">drug products</font> that have already been approved or are in     <font color="blue">development</font>,  and  operate large, well-funded research and <font color="blue">development</font>     programs  in  these  fields</td>
    </tr>
    <tr>
      <td>For example, Forteo^®, a fragment of the     full-length  <font color="blue">parathyroid hormone</font> for the treatment of <font color="blue">osteoporosis</font>, is     currently being marketed in the <font color="blue">United States </font>and Europe by Eli Lilly, Inc,     or Lilly, as a treatment for patients with <font color="blue">osteoporosis</font> who are <font color="blue">at high risk</font>     of  bone  fracture</td>
    </tr>
    <tr>
      <td>If PREOS^® is <font color="blue">approved by</font> the FDA, it <font color="blue">will compete</font>     <font color="blue">directly with</font> Forteo^® and other <font color="blue">approved therapies</font>, including <font color="blue">supplementing</font>     <font color="blue">dietary calcium</font> and vitamin D, estrogen replacement therapies, calcitonin,     <font color="blue">bisphosphonate</font> and <font color="blue">selective estrogen modulators therapies</font></td>
    </tr>
    <tr>
      <td>Many of our     <font color="blue">competitors</font> have <font color="blue">substantially</font> greater financial and <font color="blue">management</font> resources,     superior  <font color="blue">intellectual</font>  property  positions and greater <font color="blue">manufacturing</font>,     marketing and sales <font color="blue">capabilities</font>, areas in which we have limited or no     experience</td>
    </tr>
    <tr>
      <td>In addition, many of our <font color="blue">competitors</font> have <font color="blue">significant</font>ly greater     experience than we do in undertaking <font color="blue">pre<font color="blue">clinical testing</font></font> and <font color="blue">clinical trials</font>     of new or improved <font color="blue">pharmaceutical</font> products and obtaining required <font color="blue">regulatory</font>     approvals</td>
    </tr>
    <tr>
      <td>Consequently, our <font color="blue">competitors</font> may obtain FDA and other <font color="blue">regulatory</font>     approvals  for <font color="blue">product <font color="blue">candidates</font></font> sooner and may be more successful in     <font color="blue">manufacturing</font> and marketing their <font color="blue">products than</font> we or our <font color="blue"><font color="blue">collaborator</font>s</font>,     <font color="blue">which could</font> render our <font color="blue">product <font color="blue">candidates</font></font> obsolete and non-competitive</td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________       Existing and future products, therapies and <font color="blue">technological</font> approaches will     compete  directly  with  the  products we seek to develop</td>
    </tr>
    <tr>
      <td>Current and     prospective competing <font color="blue">products may</font> provide greater <font color="blue">therapeutic</font> benefits for     a  specific problem, may offer easier delivery or may offer comparable     performance at a lower cost</td>
    </tr>
    <tr>
      <td>Any <font color="blue">product candidate</font> that we develop and that     obtains <font color="blue">regulatory</font> approval must then compete for <font color="blue">market acceptance</font> and     market share</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> may not gain <font color="blue">market acceptance</font> among     physicians, patients, healthcare payors and the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>Further,     any products we develop may become obsolete before we recover any expenses     we incurred in <font color="blue">connection</font> with the <font color="blue">development</font> of these products</td>
    </tr>
    <tr>
      <td>As a     result, we may never achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We may be unable to obtain patents to protect our <font color="blue"><font color="blue">technologies</font> from</font> other     <font color="blue">companies with</font> competitive products, and patents of other <font color="blue">companies could</font>     prevent us from <font color="blue">manufacturing</font>, developing or marketing our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> firms are uncertain     and  involve  <font color="blue">complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td><font color="blue">The US Patent </font>and     <font color="blue">Trademark Office </font>has not established a <font color="blue">consistent policy</font> regarding the     breadth of claims that it will allow in bio<font color="blue">technology</font> patents</td>
    </tr>
    <tr>
      <td>If it allows     broad claims, the number and cost of <font color="blue">patent <font color="blue">interference proceedings</font></font> in the     US and the risk of <font color="blue"><font color="blue">infringement</font> litigation may increase</font></td>
    </tr>
    <tr>
      <td>If it allows     narrow claims, the risk of <font color="blue">infringement</font> may decrease, but the value of our     rights  under  our  patents, licenses and <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font> may also</font>     decrease</td>
    </tr>
    <tr>
      <td>In addition, the scope of the claims in a patent <font color="blue">application</font> can     be <font color="blue">significant</font>ly modified during prosecution before the patent is issued</td>
    </tr>
    <tr>
      <td>Consequently, we cannot know whether our <font color="blue">pending <font color="blue"><font color="blue">application</font>s</font> will</font> result in     the issuance of patents or, if any patents are issued, whether they will     provide us with <font color="blue">significant</font> <font color="blue">proprietary</font> protection or will be <font color="blue">circumvented</font>,     invalidated,  or  found  to  be  unenforceable</td>
    </tr>
    <tr>
      <td>Until recently, patent     <font color="blue"><font color="blue">application</font>s</font> in the <font color="blue">United States </font>were maintained in <font color="blue">secrecy until</font> the     <font color="blue">patents issued</font>, and <font color="blue">publication</font> of <font color="blue">discoveries</font> in scientific or patent     literature often lags behind actual <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue"><font color="blue">application</font>s</font> filed     in the <font color="blue">United States </font>after November 2000 <font color="blue">generally</font> will be published 18     months  after  the <font color="blue">filing date unless</font> the <font color="blue">applicant certifies</font> that the     <font color="blue">invention will</font> not be the subject of a <font color="blue"><font color="blue">foreign patent</font> <font color="blue">application</font></font></td>
    </tr>
    <tr>
      <td>We cannot     assure you that, even if published, we will be aware of all <font color="blue">such literature</font></td>
    </tr>
    <tr>
      <td>Accordingly, we cannot be certain that the <font color="blue">named inventors</font> of our products     and processes were the first to invent that product or process or that we     were the first to <font color="blue">pursue patent coverage</font> for our <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">commercial success depends</font> in part on our ability to maintain and     enforce our <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">third parties</font> engage in <font color="blue">activities</font> that     infringe our <font color="blue"><font color="blue">proprietary</font> rights</font>, our <font color="blue">management</font>’s focus will be diverted and     we  may incur <font color="blue">significant</font> costs in asserting our rights</td>
    </tr>
    <tr>
      <td>We may not be     successful in asserting our <font color="blue"><font color="blue">proprietary</font> rights</font>, <font color="blue">which could</font> result in our     patents being held invalid or a court holding that the <font color="blue">third party</font> is not     infringing,  either  of  <font color="blue">which would</font> harm our <font color="blue">competitive position</font></td>
    </tr>
    <tr>
      <td>In     addition,  we <font color="blue">cannot assure</font> you that <font color="blue">others will</font> not <font color="blue">design around</font> our     patented <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Moreover, we may have to <font color="blue">participate</font> in <font color="blue">interference proceedings</font> declared by     the <font color="blue">United States </font>Patent and <font color="blue">Trademark Office </font>or other <font color="blue">analogous proceedings</font>     in other parts of the world to determine priority of invention and the     validity of <font color="blue">patent rights granted</font> or applied for, <font color="blue">which could</font> result in     substantial cost and delay, even if the <font color="blue">eventual outcome</font> is favorable to us</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our pending patent <font color="blue"><font color="blue">application</font>s</font>, if issued, would     be held valid or enforceable</td>
    </tr>
    <tr>
      <td>Additionally, many of our <font color="blue">foreign patent</font>     <font color="blue"><font color="blue">application</font>s</font> have <font color="blue">been published as</font> part of the <font color="blue">patent prosecution process</font>     in <font color="blue">such countries</font></td>
    </tr>
    <tr>
      <td><font color="blue">Protection </font>of the rights revealed in <font color="blue">published patent</font>     <font color="blue"><font color="blue">application</font>s</font> can be complex, costly and uncertain</td>
    </tr>
    <tr>
      <td>In order to <font color="blue">protect goodwill associated with</font> our company and <font color="blue">product names</font>,     we <font color="blue">rely on trademark protection</font> for our marks</td>
    </tr>
    <tr>
      <td>We registered the “PREOS”     <font color="blue">trademark with</font> the <font color="blue">United States </font>Patent and Trademark Office</td>
    </tr>
    <tr>
      <td>A <font color="blue">third party</font>     may assert a claim that the PREOS^® mark is <font color="blue">confusingly</font> similar to its mark,     and  such  claims  or the failure to <font color="blue">timely register</font> the PREOS mark or     <font color="blue">objections by</font> the FDA could force us to select a new name <font color="blue">for PREOS</font>^®, which     could cause us to incur <font color="blue">additional</font> expense or delay its <font color="blue">introduction</font> to     market</td>
    </tr>
    <tr>
      <td>We also rely on <font color="blue">trade secrets</font>, know-how and <font color="blue">confidentiality provisions</font> in     our <font color="blue">agreement</font>s with our <font color="blue"><font color="blue">collaborator</font>s</font>, employees and <font color="blue">consultants</font> to protect     our <font color="blue">intellectual</font> property</td>
    </tr>
    <tr>
      <td>However, these and other <font color="blue">parties may</font> not comply     with  the terms of their <font color="blue">agreement</font>s with us, and we might be unable to     adequately  enforce our <font color="blue">rights against</font> these people or obtain adequate     <font color="blue">compensation</font> for the damages caused by their <font color="blue">unauthorized <font color="blue">disclosure</font></font> or use</td>
    </tr>
    <tr>
      <td>Our <font color="blue">trade secrets</font> or those of our <font color="blue"><font color="blue">collaborator</font>s</font> may become known or may be     <font color="blue">independently discovered by others</font></td>
    </tr>
    <tr>
      <td>Our products and <font color="blue">product <font color="blue">candidates</font></font> may infringe the <font color="blue">intellectual</font> property     rights of others, <font color="blue">which could</font> increase our costs and <font color="blue">negatively affect</font> our     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our  success  <font color="blue">also depends on avoiding <font color="blue">infringement</font></font> of the <font color="blue">proprietary</font>     <font color="blue">technologies</font> of others</td>
    </tr>
    <tr>
      <td>In particular, there may be <font color="blue">certain issued patents</font>     and  patent  <font color="blue"><font color="blue">application</font>s</font>  claiming  subject  matter  which  we or our     <font color="blue"><font color="blue">collaborator</font>s</font> may be required to license in order to research, develop or     <font color="blue">commercialize</font> at least some of our <font color="blue">product <font color="blue">candidates</font></font>, including PREOS^® and     teduglutide</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">third parties</font> may assert <font color="blue">infringement</font> or other     <font color="blue">intellectual</font>  property claims <font color="blue">against us based on</font> our patents or other     <font color="blue"><font color="blue">intellectual</font> property rights</font></td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse outcome</font> in these <font color="blue">proceedings could</font>     subject us to <font color="blue">significant</font> <font color="blue">liabilities</font>                                           25     ______________________________________________________________________       to <font color="blue">third parties</font>, require <font color="blue">disputed rights</font> to be licensed from <font color="blue">third parties</font>     or  require us to cease or modify our use of the <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>If we are     required to license such <font color="blue">technology</font>, we <font color="blue">cannot assure</font> you that a license     <font color="blue">under such patents</font> and patent <font color="blue"><font color="blue">application</font>s</font> will be <font color="blue">available on</font> acceptable     terms or at all</td>
    </tr>
    <tr>
      <td>Further, we may incur substantial <font color="blue">costs defending ourselves</font>     in <font color="blue">lawsuits against charges</font> of patent <font color="blue">infringement</font> or other <font color="blue">unlawful use</font> of     another’s <font color="blue"><font color="blue">proprietary</font> <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>We are subject to extensive government <font color="blue">regulations</font> that may cause us to     cancel or delay the <font color="blue">introduction</font> of our products to market</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> <font color="blue">activities</font> and the <font color="blue">clinical investigation</font>,     <font color="blue">manufacture</font>, <font color="blue">distribution</font> and marketing of <font color="blue">drug products</font> are subject to     extensive regulation by <font color="blue">governmental</font> <font color="blue">authorities</font> in the <font color="blue">United States </font>and     other  countries</td>
    </tr>
    <tr>
      <td>Prior to marketing in the United States, a drug must     undergo  rigorous testing and an extensive <font color="blue">regulatory</font> approval process     <font color="blue">implemented by</font> the FDA <font color="blue">under federal law</font>, including the Federal Food, Drug     and Cosmetic Act</td>
    </tr>
    <tr>
      <td>To receive approval, we or our <font color="blue"><font color="blue">collaborator</font>s</font> must, among     other things, <font color="blue">demonstrate</font> with substantial evidence from well-controlled     clinical  trials  that the product is both safe and <font color="blue">effective</font> for each     <font color="blue">indication</font> where approval is sought</td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font>upon the type, <font color="blue">complexity</font> and     novelty of the product and the nature of the disease or disorder to be     treated,  that  approval  process  can  take <font color="blue">several years</font> and require     substantial <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>Data obtained <font color="blue">from testing</font> are susceptible to     varying  <font color="blue">interpretations</font> that <font color="blue">could delay</font>, limit or prevent <font color="blue">regulatory</font>     approvals of our products</td>
    </tr>
    <tr>
      <td>Drug testing is subject to complex FDA rules and     <font color="blue">regulations</font>, including the <font color="blue">requirement</font> to <font color="blue">conduct human testing on</font> a large     number of <font color="blue">test subjects</font></td>
    </tr>
    <tr>
      <td>We, our <font color="blue"><font color="blue">collaborator</font>s</font> or the FDA <font color="blue">may suspend human</font>     trials at any time if a party believes that the <font color="blue">test subjects</font> are exposed to     unacceptable <font color="blue">health risks</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any of our product     <font color="blue">candidates</font> will be safe for human use</td>
    </tr>
    <tr>
      <td>Other <font color="blue">countries also</font> have extensive     <font color="blue"><font color="blue">requirement</font>s</font> regarding <font color="blue">clinical trials</font>, market authorization and pricing</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> vary widely from country to country, but, in     general, are subject to all of the <font color="blue">risks associated with</font> <font color="blue">United States </font>    approvals</td>
    </tr>
    <tr>
      <td>If any of our products receive <font color="blue">regulatory</font> approval, the <font color="blue">approval will</font> be     limited to those disease states and <font color="blue">conditions</font> for which the product is safe     and <font color="blue">effective</font>, as <font color="blue">demonstrate</font>d through <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>In addition, results     of pre-clinical studies and <font color="blue">clinical trials</font> <font color="blue">with respect</font> to our products     could subject us to adverse product labeling <font color="blue"><font color="blue">requirement</font>s</font> <font color="blue">which could</font> harm     the sale of <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>Even if <font color="blue">regulatory</font> approval is obtained, later     <font color="blue">discovery</font> of <font color="blue">previously unknown problems may</font> result in <font color="blue">restrictions</font> of the     product, including withdrawal of the <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>Further,     <font color="blue">governmental</font>  approval  may  subject  us  to  ongoing <font color="blue"><font color="blue">requirement</font>s</font> for     post-marketing studies</td>
    </tr>
    <tr>
      <td>Even if we obtain <font color="blue">governmental</font> approval, a marketed     product, its respective <font color="blue">manufacture</font>r and its <font color="blue">manufacturing</font> facilities are     subject to unannounced <font color="blue">inspections</font> by the FDA and <font color="blue">must <font color="blue">comply with</font></font> the     FDA’s cGMP and other <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> govern all areas of     production, record keeping, personnel and <font color="blue">quality control</font></td>
    </tr>
    <tr>
      <td>If a <font color="blue">manufacture</font>r     fails to <font color="blue">comply with</font> any of the <font color="blue">manufacturing</font> <font color="blue">regulations</font>, it may be subject     to, among other things, product seizures, recalls, fines, injunctions,     <font color="blue">suspensions</font> or <font color="blue">revocations</font> of <font color="blue">marketing licenses</font>, operating <font color="blue">restrictions</font> and     <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue">countries also</font> impose similar <font color="blue">manufacturing</font>     <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">promotional materials</font> and sales <font color="blue">activities</font> are <font color="blue">governed by</font>     FDA regulation</td>
    </tr>
    <tr>
      <td>The FDA may require us to <font color="blue">withdraw promotional</font> material, to     issue  corrected  material, or to <font color="blue">cease promotion</font> resulting in loss of     <font color="blue">credibility with</font> our customers, reduced <font color="blue">sales revenue</font> or <font color="blue">increased costs</font></td>
    </tr>
    <tr>
      <td>If  we  fail  to attract and retain <font color="blue">key employees</font>, the <font color="blue">development</font> and     <font color="blue">commercialization</font> of our <font color="blue">products may</font> be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend heavily on</font> the <font color="blue">principal members</font> of our scientific and <font color="blue">management</font>     staff</td>
    </tr>
    <tr>
      <td>The risk of being unable to     retain <font color="blue">key personnel may</font> be <font color="blue">increased by</font> the fact that we have not executed     long-term employment <font color="blue">contracts with</font> our employees</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success will</font>     also depend in large part on our ability to attract and retain other highly     <font color="blue">qualified scientific</font> and <font color="blue">management</font> personnel</td>
    </tr>
    <tr>
      <td>We face <font color="blue">competition</font> for     <font color="blue">personnel from</font> other companies, academic institutions, government entities     and  other  <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">operations</font> in Salt Lake City, Utah,     Parsippany, New Jersey, Mississauga, Ontario and Toronto, Ontario</td>
    </tr>
    <tr>
      <td>We also     have <font color="blue">executive officers at each</font> of these locations</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success will</font>     depend in part on how well we are able to <font color="blue">integrate each</font> of their efforts     with the <font color="blue">operations</font> of the Company and how successful we are in managing     personnel who are working on the same program but are spread out at various     geographic locations</td>
    </tr>
    <tr>
      <td>If we are not successful in our <font color="blue">management</font> transition or in attracting and     retaining <font color="blue">management</font> team members and other <font color="blue">highly qualified individuals</font> in     our industry, we may not be able to <font color="blue">successfully</font> implement our business     strategy</td>
    </tr>
    <tr>
      <td>Our  ability  to  compete  in the highly competitive bio<font color="blue">technology</font> and     <font color="blue">pharmaceutical</font>s industries depends in large part upon our ability to attract     and retain <font color="blue">highly qualified managerial personnel</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">historically been</font>     highly <font color="blue">dependent on</font> Dr</td>
    </tr>
    <tr>
      <td>Hunter Jackson, the founder of our company and our     only Chairman, <font color="blue">Chief Executive Officer</font> and President</td>
    </tr>
    <tr>
      <td>Jackson has held     these offices since the founding of <font color="blue">NPS to November </font>2005</td>
    </tr>
    <tr>
      <td><font color="blue">In November </font>2005,     Dr</td>
    </tr>
    <tr>
      <td><font color="blue">N Anthony Coles </font>joined NPS as <font color="blue">President and Chief Operating Officer </font>and     continues to hold these offices</td>
    </tr>
    <tr>
      <td>Jackson continues to serve as our     <font color="blue">Chairman and <font color="blue">Chief Executive Officer</font> </font>and will hold these offices until May     11, 2006, at which time he will retire</td>
    </tr>
    <tr>
      <td>Coles will     become our <font color="blue">Chief Executive Officer</font></td>
    </tr>
    <tr>
      <td><font color="blue">Jackson and Coles </font>are working     <font color="blue">together closely</font> to ensure an <font color="blue">effective</font> transition</td>
    </tr>
    <tr>
      <td>Coles <font color="blue">will continue</font>     after May 11, 2006 to work with our <font color="blue">management</font> team to accomplish, among     other things, a <font color="blue">successful transition</font> of <font color="blue">leadership</font></td>
    </tr>
    <tr>
      <td>Coles, we have hired other key members of our <font color="blue">management</font> team over the past     few years</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success depends on</font> a successful <font color="blue">management</font> transition     and will also <font color="blue">depend on</font> our continuing to attract, retain and motivate     highly skilled <font color="blue">management</font> team members</td>
    </tr>
    <tr>
      <td>If <font color="blue">product <font color="blue">liability</font></font> claims are <font color="blue">brought against us</font> or we are unable to     obtain or maintain <font color="blue">product <font color="blue">liability</font></font> insurance, we may incur substantial     <font color="blue">liabilities</font> that <font color="blue">could reduce</font> our <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical testing</font> and <font color="blue">commercial use</font> of <font color="blue">pharmaceutical</font> products involves     <font color="blue">significant</font> exposure to <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>We have obtained limited     <font color="blue">product <font color="blue">liability</font></font> <font color="blue">insurance coverage</font> for our <font color="blue">clinical trial on humans</font>,     however, our <font color="blue"><font color="blue">insurance coverage</font> may</font> be insufficient to <font color="blue">protect us against</font>     all <font color="blue">product <font color="blue">liability</font></font> damages</td>
    </tr>
    <tr>
      <td>Further, <font color="blue"><font color="blue">liability</font> <font color="blue">insurance coverage</font></font> is     becoming  <font color="blue">increasingly expensive</font> and we might not be able to obtain or     maintain <font color="blue">product <font color="blue">liability</font></font> insurance in the future on acceptable terms or in     sufficient  amounts  to  <font color="blue">protect us against</font> <font color="blue">product <font color="blue">liability</font></font> damages</td>
    </tr>
    <tr>
      <td><font color="blue">Regardless </font>of merit or <font color="blue">eventual outcome</font>, <font color="blue">liability</font> claims may result in     decreased demand for a future product, injury to reputation, withdrawal of     clinical trial volunteers, loss of revenue, costs of litigation, distraction     of <font color="blue">management</font> and substantial <font color="blue">monetary awards</font> to                                           26     ______________________________________________________________________       plaintiffs</td>
    </tr>
    <tr>
      <td>Additionally, if we are required to pay a <font color="blue">product <font color="blue">liability</font></font>     claim,  we  may  not  have  sufficient <font color="blue">financial resources</font> to complete     <font color="blue">development</font> or <font color="blue">commercialization</font> of any of our <font color="blue">product <font color="blue">candidates</font></font> and our     business and results of <font color="blue">operations</font> will be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">operations</font>  involve  <font color="blue">hazardous</font>  materials and we <font color="blue">must <font color="blue">comply with</font></font>     <font color="blue"><font color="blue">environmental</font> laws</font> and <font color="blue">regulations</font>, which can be expensive and <font color="blue">restrict how</font>     we do business</td>
    </tr>
    <tr>
      <td>Our  research and <font color="blue">development</font> <font color="blue">activities</font> involve the <font color="blue">controlled use</font> of     <font color="blue">hazardous</font> materials, radioactive compounds and other <font color="blue">potentially dangerous</font>     <font color="blue">chemicals</font> and <font color="blue">biological agents</font></td>
    </tr>
    <tr>
      <td>Although we believe our <font color="blue">safety procedures</font>     for these materials <font color="blue">comply with</font> <font color="blue">governmental</font> standards, we <font color="blue">cannot entirely</font>     eliminate  the  risk  of <font color="blue"><font color="blue">accident</font>al contamination</font> or <font color="blue">injury from</font> these     materials</td>
    </tr>
    <tr>
      <td>We currently have insurance, in amounts and <font color="blue">on terms typical</font> for     companies in <font color="blue">businesses</font> that are <font color="blue">similarly situated</font>, that <font color="blue">could cover</font> all or     a portion of a damage claim arising from our use of <font color="blue">hazardous</font> and other     materials</td>
    </tr>
    <tr>
      <td>However, if an <font color="blue">accident</font> or <font color="blue">environmental</font> discharge occurs, and we     are held liable for any resulting damages, the associated <font color="blue">liability</font> could     exceed our <font color="blue">insurance coverage</font> and our <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with changing regulation of <font color="blue">corporate governance</font> and public     <font color="blue"><font color="blue">disclosure</font> may</font> result in <font color="blue">additional</font> expenses</td>
    </tr>
    <tr>
      <td><font color="blue">Changing </font>laws, <font color="blue">regulations</font> and standards relating to <font color="blue">corporate governance</font>     and public <font color="blue">disclosure</font>, new SEC <font color="blue">regulations</font> and <font color="blue">Nasdaq National Market </font>rules     are creating <font color="blue">uncertainty</font> for <font color="blue">companies such as ours</font></td>
    </tr>
    <tr>
      <td>These new or changed     laws, <font color="blue">regulations</font> and standards are subject to varying <font color="blue">interpretations</font> in     many  cases  due  to their lack of <font color="blue">specificity</font>, and as a result, their     <font color="blue">application</font> in <font color="blue">practice may evolve over</font> time <font color="blue">as new guidance</font> is <font color="blue">provided by</font>     <font color="blue">regulatory</font>  and  governing  bodies,  which  could result in continuing     <font color="blue">uncertainty</font> regarding <font color="blue">compliance matters</font> and <font color="blue">higher costs necessitated by</font>     <font color="blue">ongoing revisions</font> to <font color="blue">disclosure</font> and <font color="blue">governance practices</font></td>
    </tr>
    <tr>
      <td>We are committed     to maintaining <font color="blue">high standards</font> of <font color="blue">corporate governance</font> and public <font color="blue">disclosure</font></td>
    </tr>
    <tr>
      <td>As a result, our efforts to <font color="blue">comply with</font> evolving laws, <font color="blue">regulations</font> and     standards  have  resulted in, and are likely to continue to result in,     <font color="blue">increased general</font> and <font color="blue">administrative expenses</font> and <font color="blue">management</font> time related to     compliance <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>In particular, our efforts to <font color="blue">comply with</font> Section 404     of the Sarbanes-Oxley Act of 2002 and the related <font color="blue">regulations</font> regarding our     required <font color="blue">assessment</font> of our <font color="blue">internal controls over financial</font> reporting and     our external auditors’ audit of that <font color="blue">assessment</font> has required the <font color="blue">commitment</font>     of <font color="blue">significant</font> financial and <font color="blue">managerial resources</font></td>
    </tr>
    <tr>
      <td>We expect these efforts     to require the continued <font color="blue">commitment</font> of <font color="blue">significant</font> resources</td>
    </tr>
    <tr>
      <td>If our efforts     to <font color="blue">comply with</font> new or changed laws, <font color="blue">regulations</font> and <font color="blue">standards differ from</font>     the <font color="blue">activities</font> intended by <font color="blue">regulatory</font> or <font color="blue">governing bodies due</font> to <font color="blue">ambiguities</font>     related to practice, our <font color="blue">reputation may</font> be harmed and we might be subject to     sanctions or investigation by <font color="blue">regulatory</font> <font color="blue">authorities</font>, such as the <font color="blue">Securities     </font>and  Exchange  Commission</td>
    </tr>
    <tr>
      <td>Any such action could <font color="blue">adversely</font> affect our     financial results and the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Common Stock and Notes Payable        Our stock price has been and <font color="blue">may continue</font> to be volatile and an <font color="blue">investment</font>     in our <font color="blue">common stock</font> could suffer a decline in value</td>
    </tr>
    <tr>
      <td>You should consider an <font color="blue">investment</font> in our <font color="blue">common stock</font> as risky and invest     only if you can withstand a <font color="blue">significant</font> loss and <font color="blue">wide <font color="blue">fluctuations</font></font> in the     market  value of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We receive only limited <font color="blue">attention by</font>     <font color="blue">securities analysts</font> and <font color="blue">frequently</font> experience an <font color="blue">imbalance between supply</font>     and demand for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> has     been highly volatile and is likely to continue to be volatile</td>
    </tr>
    <tr>
      <td><font color="blue">Factors     </font><font color="blue">affecting</font> our <font color="blue">common stock</font> price include:           •   <font color="blue">fluctuations</font> in our operating results;           •   <font color="blue">announcements</font> of <font color="blue">technological</font> innovations or <font color="blue">new commercial products</font>     by us, our <font color="blue"><font color="blue">collaborator</font>s</font> or our <font color="blue">competitors</font>;           •   published reports by <font color="blue">securities analysts</font>;           •   the progress of our and our <font color="blue"><font color="blue">collaborator</font>s</font>’ <font color="blue">clinical trials</font>, including     our and our <font color="blue"><font color="blue">collaborator</font>s</font>’ ability to produce <font color="blue">clinical supplies</font> of our     <font color="blue"><font color="blue">product <font color="blue">candidates</font></font> on</font> a <font color="blue">timely basis</font> and in <font color="blue">sufficient quantities</font> to meet     our clinical trial <font color="blue"><font color="blue">requirement</font>s</font>;           •   <font color="blue">governmental</font> regulation and changes in medical and <font color="blue">pharmaceutical</font>     product <font color="blue">reimbursement</font> policies;           •   <font color="blue">development</font>s in patent or other <font color="blue"><font color="blue">intellectual</font> property rights</font>;           •   publicity concerning the <font color="blue">discovery</font> and <font color="blue">development</font> <font color="blue">activities</font> by our     licensees;           •   public concern as to the safety and efficacy of drugs that we and our     <font color="blue">competitors</font> develop; and           •   general market <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>27     ______________________________________________________________________       <font color="blue">Antitakeover  </font>provisions  in our Certificate of Incorporation, Bylaws,     <font color="blue">stockholder rights</font> plan and under <font color="blue">Delaware </font><font color="blue">law may discourage</font> or prevent a     change of control</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our Certificate of Incorporation and Bylaws and Section 203 of     the <font color="blue">Delaware </font>General Corporation Law <font color="blue">could delay</font> or prevent a change of     control  of  us</td>
    </tr>
    <tr>
      <td>For example, our Board of Directors, <font color="blue">without further</font>     stockholder approval, may issue preferred stock that <font color="blue">could delay</font> or prevent     a change of <font color="blue">control as well as reduce</font> the <font color="blue">voting power</font> of the holders of     <font color="blue">common stock</font>, even to the extent of <font color="blue">losing control</font> to others</td>
    </tr>
    <tr>
      <td>In addition,     our <font color="blue">Board of Directors </font>has adopted a <font color="blue">stockholder rights</font> plan, <font color="blue">commonly known</font>     as a “<font color="blue">poison pill</font>,” that may delay or prevent a change of control</td>
    </tr>
    <tr>
      <td><font color="blue">Substantial  </font><font color="blue">future sales</font> of our <font color="blue">common stock</font> by us or by our existing     <font color="blue">stockholders</font> could cause our stock price to fall</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">equity financings</font> or other share issuances by us could <font color="blue">adversely</font>     affect the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Sales by existing <font color="blue">stockholders</font>     of a large number of shares of our <font color="blue">common stock</font> in the <font color="blue">public market</font> and the     sale  of  <font color="blue">shares issued</font> in <font color="blue">connection</font> with strategic alliances, or the     <font color="blue">perception</font> that such <font color="blue">additional</font> sales could occur, could cause the market     price of our <font color="blue">common stock</font> to drop</td>
    </tr>
    <tr>
      <td>Our <font color="blue">cash flow may</font> not be sufficient to <font color="blue">cover <font color="blue">interest payments on</font></font> the 3prca     <font color="blue">Convertible Notes </font>due 2008 or to repay the notes <font color="blue">at maturity</font></td>
    </tr>
    <tr>
      <td>Our  ability  to make <font color="blue">interest payments on</font> and to repay <font color="blue">at maturity</font> or     refinance our 3prca <font color="blue">Convertible Notes </font>due 2008 <font color="blue">will <font color="blue">depend on</font></font> our ability to     <font color="blue"><font color="blue">generate sufficient</font> cash</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">never generated</font> positive <font color="blue">annual cash flow</font>     from our operating <font color="blue">activities</font>, and we may not generate or sustain positive     cash flows from <font color="blue">operations</font> in the future</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">generate sufficient</font>     cash  flow <font color="blue">will <font color="blue">depend on</font></font> our ability, or the ability of our strategic     partners, to <font color="blue">successfully</font> develop and obtain <font color="blue">regulatory</font> approval for new     products and to <font color="blue">successfully</font> market these products, as well as the results     of our research and <font color="blue"><font color="blue">development</font> efforts</font> and other factors, including general     economic, financial, competitive, <font color="blue">legislative</font> and <font color="blue">regulatory</font> <font color="blue">conditions</font>,     many of which are outside of our control</td>
    </tr>
    <tr>
      <td><font color="blue">Conversion </font>of the notes <font color="blue">will dilute</font> the <font color="blue">ownership interest</font> of existing     <font color="blue">stockholders</font>, including holders who had <font color="blue">previously converted</font> their notes</td>
    </tr>
    <tr>
      <td>The  <font color="blue">conversion</font>  of some or all of the notes <font color="blue">will dilute</font> the ownership     interests of existing <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Any sales in the <font color="blue">public market</font> of the     <font color="blue">common stock</font> issuable upon such <font color="blue">conversion</font> could <font color="blue">adversely</font> affect prevailing     <font color="blue">market price</font>s of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, the existence of the notes     <font color="blue">may encourage</font> short <font color="blue">selling by market participants</font></td>
    </tr>
    <tr>
      <td>Royalty and milestone revenues received from Amgen on sales of <font color="blue">cinacalcet</font>     HCl may not be sufficient to cover the interest and <font color="blue">principal payments on</font>     the Secured 8dtta0prca Notes due March 30, 2017</td>
    </tr>
    <tr>
      <td>As a result, we would have to     either make such <font color="blue">payments out</font> of <font color="blue">available cash resources</font> or risk <font color="blue">forfeiture</font>     of certain royalty <font color="blue">rights under</font> <font color="blue">the Amgen </font><font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2004, we completed a <font color="blue">private placement</font> of dlra175dtta0 million in     secured 8dtta0prca Notes due March 30, 2017, or <font color="blue">Secured Notes</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">Secured Notes</font>     are non-recourse to us and are <font color="blue">secured by certain royalty</font> and related rights     of the <font color="blue">company under</font> our <font color="blue">agreement</font> with Amgen</td>
    </tr>
    <tr>
      <td>Additionally, the principal     sources for interest payments and principal repayment of the <font color="blue">Secured Notes</font>     is limited to royalty and <font color="blue">milestone payments</font> received from Amgen</td>
    </tr>
    <tr>
      <td>If the     revenues received from Amgen are insufficient to cover the interest and     other <font color="blue">payments due under</font> the secured Notes we would have to either make the     <font color="blue">payments out</font> of <font color="blue">available cash resources</font> or forfeit our rights to royalties     and other <font color="blue">rights under</font> <font color="blue">the Amgen </font><font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>If we elect to make the payments     our  <font color="blue">cash resources would</font> be <font color="blue">significant</font>ly reduced and we may not have     <font color="blue">sufficient cash resources</font> to fund our programs and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we do not     make the <font color="blue">payments due under</font> the <font color="blue">Secured Notes</font> then we risk losing the future     <font color="blue">revenue stream from</font> Amgen for sales of <font color="blue">cinacalcet</font> HCl <font color="blue">which could</font> <font color="blue">adversely</font>     effect <font color="blue">future cash resources</font> and we <font color="blue">would lose rights</font> to the <font color="blue">technology</font>     licensed to Amgen under <font color="blue">the Amgen </font><font color="blue">agreement</font></td>
    </tr>
  </tbody>
</table>